Month: February 2017

GCP Renovation – Modernization of ICH E8 and Subsequent Renovation of ICH E6

“ICH is inviting public review and comment on a reflection paper on Good Clinical Practice (GCP) “Renovation”, which contains the ICH proposal for further modernization of the ICH Guidelines related to clinical trial design, planning, management, and conduct. The scope of the proposed renovation includes the current E8 General Considerations for Clinical Trials and further revision to the E6 Guideline for Good Clinical Practice, which is already undergoing modernization with the recent production of ICH E6(R2).”

For detailed information please see the Reflection paper on GCP Renovation

All comments should be submitted before the closing date for public comment, which is March 11, 2017.

 

FDA’s Draft Guidances for the calendar year 2017

The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has published a Guidance Agenda with planned new and revised Draft Guidances for the calendar year 2017.

Changes are expected within documents of several categories: Advertising, Biopharmaceutics, Biosimilarity, Clinical/Antimicrobial, Clinical/Medical, Clinical Pharmacology, Clinical/Statistical, Drug Safety, Electronic Submissions, Generics, Labeling, Pharmaceutical Quality/CMC, Pharmaceutical Quality/Manufacturing Standards (CGMP), Pharmacology/Toxicology, Procedural, User Fees

 

Agreement between the EEA Heads of Medicines Agencies and the Pharmaceutical Inspection Co-operation Scheme

The Heads of Medicines Agencies of the European Economic Area (EEA HMA) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) signed a Letter of Agreement. The objective of the agreement is the exchange of information after audits among authorities and joint training for GxP inspectors. The agreement came into force August 2016.

Novelty of the medical device Regulation proposal concerning Responsible Person

According to Article 13 of the draft medical device Regulation entitled “Person responsible for regulatory compliance” as lastly amended by the European Parliament, “manufacturers must have available within their organization at least one person responsible for regulatory compliance who possesses the requisite expertise in the field of medical devices”. Hence, the main change in medical device Regulation proposal is the requirement that a qualified person of manufacturer’s organization or authorized representative should be responsible for regulatory compliance.

Interestingly, professional experience can replace an academic qualification. In contrast to the requirements for the qualified person for medicinal products, the responsible person for medical devices can rely on either a diploma or a professional experience. Moreover, this amendment of the  European Parliament enables that the role and responsibilities may be shared between several persons responsible for example for one of these tasks: regulatory, production or quality assurance compliance.

More on the topic you can read here and here

Nowe wytyczne GMP dla badanych produktów leczniczych

W związku z nowym rozporządzeniem UE w sprawie Dobrej Praktyki Klinicznej 536/2014 Komisja UE opublikowała w dniu 16 września …

Nowelizacja Prawa Farmaceutycznego

Będąca w pracach komisji prawniczej nowela Prawa Farmaceutycznego przyniesie zmiany dla wytwórców produktów leczniczych …

Rewizja wytycznych dotyczących produktów leczniczych zawierających genetycznie zmodyfikowane komórki

Wytyczne z 2012 r. koncentrowały się na tradycyjnych metodach modyfikacji genetycznej komórek opartych na wykorzystaniu …